Drugs / CHO-V08
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07016152 | Jun 2025 → Nov 2026 expected | Klebsiella pneumonia | Cho Pharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHO-V08 | “CHO-V08 is a glycoconjugate bivalent vaccine in sterile suspension.” NCT07016152 ↗ |
| Modality | Vaccine | “CHO-V08 is a glycoconjugate bivalent vaccine in sterile suspension.” NCT07016152 ↗ |